Mesa Laboratories (NASDAQ:MLAB) CFO Sells $123,853.21 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CFO John Sakys sold 1,223 shares of Mesa Laboratories stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $101.27, for a total transaction of $123,853.21. Following the sale, the chief financial officer owned 16,538 shares in the company, valued at approximately $1,674,803.26. This represents a 6.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mesa Laboratories Price Performance

Mesa Laboratories stock traded down $4.85 during midday trading on Wednesday, hitting $94.84. The company’s stock had a trading volume of 154,655 shares, compared to its average volume of 136,917. The company has a quick ratio of 1.29, a current ratio of 1.72 and a debt-to-equity ratio of 0.78. The stock’s 50-day moving average price is $101.88 and its 200-day moving average price is $90.54. Mesa Laboratories, Inc. has a 12 month low of $55.45 and a 12 month high of $113.99. The company has a market capitalization of $523.96 million, a PE ratio of 79.03 and a beta of 0.94.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 EPS for the quarter, missing the consensus estimate of $1.78 by ($0.25). Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.The business had revenue of $63.72 million during the quarter, compared to the consensus estimate of $65.21 million. During the same quarter last year, the firm posted ($1.31) earnings per share.

Mesa Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 15th. Shareholders of record on Friday, May 29th were given a $0.16 dividend. The ex-dividend date was Friday, May 29th. This represents a $0.64 annualized dividend and a yield of 0.7%. Mesa Laboratories’s payout ratio is 53.33%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, June 3rd. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Mesa Laboratories has a consensus rating of “Reduce” and a consensus price target of $94.00.

Hedge Funds Weigh In On Mesa Laboratories

A number of institutional investors have recently bought and sold shares of MLAB. Royal Bank of Canada increased its stake in Mesa Laboratories by 1.2% in the 1st quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier’s stock worth $3,652,000 after purchasing an additional 353 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Mesa Laboratories in the 1st quarter worth about $335,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Mesa Laboratories by 4.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock worth $364,000 after purchasing an additional 143 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Mesa Laboratories by 3.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier’s stock worth $2,370,000 after purchasing an additional 685 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Mesa Laboratories by 1.5% in the 2nd quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock worth $1,265,000 after purchasing an additional 194 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.